User login
Key clinical point: Under real-life settings, aflibercept-FOLFIRI appeared to be a feasible second-line treatment for metastatic colorectal cancer (mCRC) with progression-free survival (PFS) of more than 12 months in the first-line therapy being the only predictive marker for better survival.
Major finding: Overall, the median overall survival and PFS was 13 (95% confidence interval [CI], 10-18) months and 6 (95% CI, 5-7) months, respectively. The overall response rate and disease control rate were 12.3% and 49.1%, respectively. The PFS of more than 12 months in the first-line chemotherapy was associated with better survival (hazard ratio, 0.32; P = .01). Most nonhematological malignancies were grade 1 or 2, whereas hypertension (18.4%) and venous thromboembolism (16.3%) were the most commonly reported grade 3-4 adverse events.
Study details: Findings are from a retrospective analysis of 49 patients with mCRC who progressed after first-line oxaliplatin-based chemotherapy and received second-line treatment with aflibercept in combination with FOLFIRI.
Disclosures: The study received no external funding. The authors declared no conflict of interests.
Source: Lavacchi D et al. Cancers (Basel). 2021 Jul 31. doi: 10.3390/cancers13153863.
Key clinical point: Under real-life settings, aflibercept-FOLFIRI appeared to be a feasible second-line treatment for metastatic colorectal cancer (mCRC) with progression-free survival (PFS) of more than 12 months in the first-line therapy being the only predictive marker for better survival.
Major finding: Overall, the median overall survival and PFS was 13 (95% confidence interval [CI], 10-18) months and 6 (95% CI, 5-7) months, respectively. The overall response rate and disease control rate were 12.3% and 49.1%, respectively. The PFS of more than 12 months in the first-line chemotherapy was associated with better survival (hazard ratio, 0.32; P = .01). Most nonhematological malignancies were grade 1 or 2, whereas hypertension (18.4%) and venous thromboembolism (16.3%) were the most commonly reported grade 3-4 adverse events.
Study details: Findings are from a retrospective analysis of 49 patients with mCRC who progressed after first-line oxaliplatin-based chemotherapy and received second-line treatment with aflibercept in combination with FOLFIRI.
Disclosures: The study received no external funding. The authors declared no conflict of interests.
Source: Lavacchi D et al. Cancers (Basel). 2021 Jul 31. doi: 10.3390/cancers13153863.
Key clinical point: Under real-life settings, aflibercept-FOLFIRI appeared to be a feasible second-line treatment for metastatic colorectal cancer (mCRC) with progression-free survival (PFS) of more than 12 months in the first-line therapy being the only predictive marker for better survival.
Major finding: Overall, the median overall survival and PFS was 13 (95% confidence interval [CI], 10-18) months and 6 (95% CI, 5-7) months, respectively. The overall response rate and disease control rate were 12.3% and 49.1%, respectively. The PFS of more than 12 months in the first-line chemotherapy was associated with better survival (hazard ratio, 0.32; P = .01). Most nonhematological malignancies were grade 1 or 2, whereas hypertension (18.4%) and venous thromboembolism (16.3%) were the most commonly reported grade 3-4 adverse events.
Study details: Findings are from a retrospective analysis of 49 patients with mCRC who progressed after first-line oxaliplatin-based chemotherapy and received second-line treatment with aflibercept in combination with FOLFIRI.
Disclosures: The study received no external funding. The authors declared no conflict of interests.
Source: Lavacchi D et al. Cancers (Basel). 2021 Jul 31. doi: 10.3390/cancers13153863.